Tuberculosis vaccines: Opportunities and challenges
ABSTRACT Tuberculosis (TB) is a serious disease around the world. Bacillus Calmette–Guérin (BCG) is the only TB vaccine licensed for use in human beings, and is effective in protecting infants and children against severe miliary and meningeal TB. However, BCG's protective efficacy is variable i...
Gespeichert in:
| Veröffentlicht in: | Respirology (Carlton, Vic.) Vic.), 2018-04, Vol.23 (4), p.359-368 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 368 |
|---|---|
| container_issue | 4 |
| container_start_page | 359 |
| container_title | Respirology (Carlton, Vic.) |
| container_volume | 23 |
| creator | Zhu, Bingdong Dockrell, Hazel M. Ottenhoff, Tom H.M. Evans, Thomas G. Zhang, Ying |
| description | ABSTRACT
Tuberculosis (TB) is a serious disease around the world. Bacillus Calmette–Guérin (BCG) is the only TB vaccine licensed for use in human beings, and is effective in protecting infants and children against severe miliary and meningeal TB. However, BCG's protective efficacy is variable in adults. Novel TB vaccine candidates being developed include whole‐cell vaccines (recombinant BCG (rBCG), attenuated Mycobacterium tuberculosis, killed M. tuberculosis or Mycobacterium vaccae), adjuvanted protein subunit vaccines, viral vector‐delivered subunit vaccines, plasmid DNA vaccines, RNA‐based vaccines etc. At least 12 novel TB vaccine candidates are now in clinical trials, including killed M. vaccae, rBCG ΔureC::hly, adjuvanted fusion proteins M72 and H56 and viral vectored MVA85A. Unfortunately, in TB, there are no correlates of vaccine‐induced protection, although cell‐mediated immune responses such as interferon‐gamma (IFN‐γ) production are widely used to assess vaccine's immunogenicity. Recent studies suggested that central memory T cells and local secreted IgA correlated with protection against TB disease. Clinical TB vaccine efficacy trials should invest in identifying correlates of protection, and evaluate new TB biomarkers emerging from human and animal studies. Accumulating new knowledge on M. tuberculosis antigens and immune profiles correlating with protection or disease risk will be of great help in designing next generation of TB vaccines. |
| doi_str_mv | 10.1111/resp.13245 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989611735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1989611735</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4595-38538a88100995d550651b590de79d78cfd30f20b5c6b4fe20071a6d1e8d96413</originalsourceid><addsrcrecordid>eNp90E1Lw0AQBuBFFFurF3-ABLyIkDqT3U2y3qTUDyhUtJ6Xze5GU9Ik7jZK_72pqR48OJeZw8PL8BJyijDGbq6c9c0YacT4HhkiYxBiyuh-d9OIhkkixIAceb8EAMqBH5JBJChDRmFI6KLNrNNtWfvCBx9K66Ky_jqYN03t1m1VrAvrA1WZQL-psrTVq_XH5CBXpbcnuz0iL7fTxeQ-nM3vHiY3s1AzLnhIU05TlaYIIAQ3nEPMMeMCjE2ESVKdGwp5BBnXccZyGwEkqGKDNjUiZkhH5KLPbVz93lq_lqvCa1uWqrJ16yWKVMSICeUdPf9Dl3Xrqu47GQHSjiDQTl32Srvae2dz2bhipdxGIshtlXJbpfyussNnu8g2W1nzS3-66wD24LMo7eafKPk0fX7sQ78AL118FA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2013735103</pqid></control><display><type>article</type><title>Tuberculosis vaccines: Opportunities and challenges</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zhu, Bingdong ; Dockrell, Hazel M. ; Ottenhoff, Tom H.M. ; Evans, Thomas G. ; Zhang, Ying</creator><creatorcontrib>Zhu, Bingdong ; Dockrell, Hazel M. ; Ottenhoff, Tom H.M. ; Evans, Thomas G. ; Zhang, Ying</creatorcontrib><description>ABSTRACT
Tuberculosis (TB) is a serious disease around the world. Bacillus Calmette–Guérin (BCG) is the only TB vaccine licensed for use in human beings, and is effective in protecting infants and children against severe miliary and meningeal TB. However, BCG's protective efficacy is variable in adults. Novel TB vaccine candidates being developed include whole‐cell vaccines (recombinant BCG (rBCG), attenuated Mycobacterium tuberculosis, killed M. tuberculosis or Mycobacterium vaccae), adjuvanted protein subunit vaccines, viral vector‐delivered subunit vaccines, plasmid DNA vaccines, RNA‐based vaccines etc. At least 12 novel TB vaccine candidates are now in clinical trials, including killed M. vaccae, rBCG ΔureC::hly, adjuvanted fusion proteins M72 and H56 and viral vectored MVA85A. Unfortunately, in TB, there are no correlates of vaccine‐induced protection, although cell‐mediated immune responses such as interferon‐gamma (IFN‐γ) production are widely used to assess vaccine's immunogenicity. Recent studies suggested that central memory T cells and local secreted IgA correlated with protection against TB disease. Clinical TB vaccine efficacy trials should invest in identifying correlates of protection, and evaluate new TB biomarkers emerging from human and animal studies. Accumulating new knowledge on M. tuberculosis antigens and immune profiles correlating with protection or disease risk will be of great help in designing next generation of TB vaccines.</description><identifier>ISSN: 1323-7799</identifier><identifier>EISSN: 1440-1843</identifier><identifier>DOI: 10.1111/resp.13245</identifier><identifier>PMID: 29341430</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Antigens ; Bacillus Calmette-Guerin vaccine ; BCG ; biomarkers ; Children ; Clinical trials ; DNA vaccines ; Immune response ; immunity ; Immunogenicity ; Immunoglobulin A ; Immunological memory ; Infants ; Lymphocytes T ; Memory cells ; Ribonucleic acid ; RNA ; Tuberculosis ; Vaccine efficacy ; Vaccines</subject><ispartof>Respirology (Carlton, Vic.), 2018-04, Vol.23 (4), p.359-368</ispartof><rights>2018 Asian Pacific Society of Respirology</rights><rights>2018 Asian Pacific Society of Respirology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4595-38538a88100995d550651b590de79d78cfd30f20b5c6b4fe20071a6d1e8d96413</citedby><cites>FETCH-LOGICAL-c4595-38538a88100995d550651b590de79d78cfd30f20b5c6b4fe20071a6d1e8d96413</cites><orcidid>0000-0001-8422-4594</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fresp.13245$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fresp.13245$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29341430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Bingdong</creatorcontrib><creatorcontrib>Dockrell, Hazel M.</creatorcontrib><creatorcontrib>Ottenhoff, Tom H.M.</creatorcontrib><creatorcontrib>Evans, Thomas G.</creatorcontrib><creatorcontrib>Zhang, Ying</creatorcontrib><title>Tuberculosis vaccines: Opportunities and challenges</title><title>Respirology (Carlton, Vic.)</title><addtitle>Respirology</addtitle><description>ABSTRACT
Tuberculosis (TB) is a serious disease around the world. Bacillus Calmette–Guérin (BCG) is the only TB vaccine licensed for use in human beings, and is effective in protecting infants and children against severe miliary and meningeal TB. However, BCG's protective efficacy is variable in adults. Novel TB vaccine candidates being developed include whole‐cell vaccines (recombinant BCG (rBCG), attenuated Mycobacterium tuberculosis, killed M. tuberculosis or Mycobacterium vaccae), adjuvanted protein subunit vaccines, viral vector‐delivered subunit vaccines, plasmid DNA vaccines, RNA‐based vaccines etc. At least 12 novel TB vaccine candidates are now in clinical trials, including killed M. vaccae, rBCG ΔureC::hly, adjuvanted fusion proteins M72 and H56 and viral vectored MVA85A. Unfortunately, in TB, there are no correlates of vaccine‐induced protection, although cell‐mediated immune responses such as interferon‐gamma (IFN‐γ) production are widely used to assess vaccine's immunogenicity. Recent studies suggested that central memory T cells and local secreted IgA correlated with protection against TB disease. Clinical TB vaccine efficacy trials should invest in identifying correlates of protection, and evaluate new TB biomarkers emerging from human and animal studies. Accumulating new knowledge on M. tuberculosis antigens and immune profiles correlating with protection or disease risk will be of great help in designing next generation of TB vaccines.</description><subject>Antigens</subject><subject>Bacillus Calmette-Guerin vaccine</subject><subject>BCG</subject><subject>biomarkers</subject><subject>Children</subject><subject>Clinical trials</subject><subject>DNA vaccines</subject><subject>Immune response</subject><subject>immunity</subject><subject>Immunogenicity</subject><subject>Immunoglobulin A</subject><subject>Immunological memory</subject><subject>Infants</subject><subject>Lymphocytes T</subject><subject>Memory cells</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Tuberculosis</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><issn>1323-7799</issn><issn>1440-1843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp90E1Lw0AQBuBFFFurF3-ABLyIkDqT3U2y3qTUDyhUtJ6Xze5GU9Ik7jZK_72pqR48OJeZw8PL8BJyijDGbq6c9c0YacT4HhkiYxBiyuh-d9OIhkkixIAceb8EAMqBH5JBJChDRmFI6KLNrNNtWfvCBx9K66Ky_jqYN03t1m1VrAvrA1WZQL-psrTVq_XH5CBXpbcnuz0iL7fTxeQ-nM3vHiY3s1AzLnhIU05TlaYIIAQ3nEPMMeMCjE2ESVKdGwp5BBnXccZyGwEkqGKDNjUiZkhH5KLPbVz93lq_lqvCa1uWqrJ16yWKVMSICeUdPf9Dl3Xrqu47GQHSjiDQTl32Srvae2dz2bhipdxGIshtlXJbpfyussNnu8g2W1nzS3-66wD24LMo7eafKPk0fX7sQ78AL118FA</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Zhu, Bingdong</creator><creator>Dockrell, Hazel M.</creator><creator>Ottenhoff, Tom H.M.</creator><creator>Evans, Thomas G.</creator><creator>Zhang, Ying</creator><general>John Wiley & Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8422-4594</orcidid></search><sort><creationdate>201804</creationdate><title>Tuberculosis vaccines: Opportunities and challenges</title><author>Zhu, Bingdong ; Dockrell, Hazel M. ; Ottenhoff, Tom H.M. ; Evans, Thomas G. ; Zhang, Ying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4595-38538a88100995d550651b590de79d78cfd30f20b5c6b4fe20071a6d1e8d96413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antigens</topic><topic>Bacillus Calmette-Guerin vaccine</topic><topic>BCG</topic><topic>biomarkers</topic><topic>Children</topic><topic>Clinical trials</topic><topic>DNA vaccines</topic><topic>Immune response</topic><topic>immunity</topic><topic>Immunogenicity</topic><topic>Immunoglobulin A</topic><topic>Immunological memory</topic><topic>Infants</topic><topic>Lymphocytes T</topic><topic>Memory cells</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Tuberculosis</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Bingdong</creatorcontrib><creatorcontrib>Dockrell, Hazel M.</creatorcontrib><creatorcontrib>Ottenhoff, Tom H.M.</creatorcontrib><creatorcontrib>Evans, Thomas G.</creatorcontrib><creatorcontrib>Zhang, Ying</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Respirology (Carlton, Vic.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Bingdong</au><au>Dockrell, Hazel M.</au><au>Ottenhoff, Tom H.M.</au><au>Evans, Thomas G.</au><au>Zhang, Ying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tuberculosis vaccines: Opportunities and challenges</atitle><jtitle>Respirology (Carlton, Vic.)</jtitle><addtitle>Respirology</addtitle><date>2018-04</date><risdate>2018</risdate><volume>23</volume><issue>4</issue><spage>359</spage><epage>368</epage><pages>359-368</pages><issn>1323-7799</issn><eissn>1440-1843</eissn><abstract>ABSTRACT
Tuberculosis (TB) is a serious disease around the world. Bacillus Calmette–Guérin (BCG) is the only TB vaccine licensed for use in human beings, and is effective in protecting infants and children against severe miliary and meningeal TB. However, BCG's protective efficacy is variable in adults. Novel TB vaccine candidates being developed include whole‐cell vaccines (recombinant BCG (rBCG), attenuated Mycobacterium tuberculosis, killed M. tuberculosis or Mycobacterium vaccae), adjuvanted protein subunit vaccines, viral vector‐delivered subunit vaccines, plasmid DNA vaccines, RNA‐based vaccines etc. At least 12 novel TB vaccine candidates are now in clinical trials, including killed M. vaccae, rBCG ΔureC::hly, adjuvanted fusion proteins M72 and H56 and viral vectored MVA85A. Unfortunately, in TB, there are no correlates of vaccine‐induced protection, although cell‐mediated immune responses such as interferon‐gamma (IFN‐γ) production are widely used to assess vaccine's immunogenicity. Recent studies suggested that central memory T cells and local secreted IgA correlated with protection against TB disease. Clinical TB vaccine efficacy trials should invest in identifying correlates of protection, and evaluate new TB biomarkers emerging from human and animal studies. Accumulating new knowledge on M. tuberculosis antigens and immune profiles correlating with protection or disease risk will be of great help in designing next generation of TB vaccines.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>29341430</pmid><doi>10.1111/resp.13245</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8422-4594</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1323-7799 |
| ispartof | Respirology (Carlton, Vic.), 2018-04, Vol.23 (4), p.359-368 |
| issn | 1323-7799 1440-1843 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1989611735 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Antigens Bacillus Calmette-Guerin vaccine BCG biomarkers Children Clinical trials DNA vaccines Immune response immunity Immunogenicity Immunoglobulin A Immunological memory Infants Lymphocytes T Memory cells Ribonucleic acid RNA Tuberculosis Vaccine efficacy Vaccines |
| title | Tuberculosis vaccines: Opportunities and challenges |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T09%3A06%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tuberculosis%20vaccines:%20Opportunities%20and%20challenges&rft.jtitle=Respirology%20(Carlton,%20Vic.)&rft.au=Zhu,%20Bingdong&rft.date=2018-04&rft.volume=23&rft.issue=4&rft.spage=359&rft.epage=368&rft.pages=359-368&rft.issn=1323-7799&rft.eissn=1440-1843&rft_id=info:doi/10.1111/resp.13245&rft_dat=%3Cproquest_cross%3E1989611735%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2013735103&rft_id=info:pmid/29341430&rfr_iscdi=true |